Business Wire

OH-PRVEN-OPTCS/CLDGENERA

12.8.2024 14:01:30 CEST | Business Wire | Press release

Share
Proven Optics Acquires CloudGenera

Proven Optics, a premier IT Financial Management Solution provider, today announced the acquisition of CloudGenera, a provider of innovative cloud financial optimization solutions, furthering its mission to create the industry’s most complete IT financial management application platform. The CloudGenera acquisition is the first of what the company anticipates will be several acquisitions as Proven Optics scales growth and leverages a majority growth investment from Silversmith Capital Partners and strategic investment from ServiceNow.

CloudGenera offers vendor-agnostic IT analytics that equip organizations with the business cases necessary to optimize their technology expenditures. By leveraging advanced AI and machine learning technologies, CloudGenera automates decisions regarding application migration and modernization and significantly improves the accuracy of cloud cost forecasts, thus enhancing IT decision-making processes.

“The acquisition of CloudGenera marks a significant milestone for Proven Optics as we expand our cloud costing product capabilities,” said William Miller, Founding Partner & Co-CEO of Proven Optics. “Together, Proven Optics and CloudGenera will provide a more complete solution that provides our customers with new IT decision analysis capabilities to generate business cases for cloud migration and optimization.”

Proven Optics was founded in 2020 to provide IT and finance leaders with the necessary analytics and insights to make better business decisions by automating the financial management of complex IT budgets. Delivered on the ServiceNow Platform and available in the ServiceNow Store, the Proven Optics Financial Management Application Suite offers additional value for ServiceNow customers looking to add a financial lens to their decision-making.

The acquisition enhances the value that Proven Optics’ customers derive from their investment in ServiceNow as a strategic platform. By offering critical market intelligence, both Proven Optics and CloudGenera customers will benefit from an integrated solution that improves cloud orchestration and decisions related to budgeting and future forecasting, allowing IT finance and cloud teams to manage the entire process within a single workflow and take full advantage of the power of the ServiceNow platform.

“We are excited to join forces with Bill, Ben, and the entire Proven Optics team,” said Brian Kelly, Founder and CEO of CloudGenera who has joined Proven Optics as Executive Vice President of Product. “Together, we will provide customers with a comprehensive set of tools to enhance IT value and facilitate smarter decision-making across their cloud infrastructure.”

About Proven Optics

Proven Optics is a software company that focuses on one thing: Financial Management. Proven Optics helps clients in both IT and finance organizations implement financial management toolsets on the ServiceNow platform, leveraging 20+ years of practitioner experience and 100+ Commercial and Federal implementations. Our solutions enable modernization of financial management functions, providing IT and Finance leaders with the necessary analytics and insights to make better business decisions. For more information or a demonstration of our products, please visit www.provenoptics.com.

About CloudGenera

Founded in 2012, CloudGenera supplies vendor-agnostic IT analytics that arm organizations with the business cases needed to optimize their technology spend. CloudGenera’s proprietary algorithms automate application migration and modernization decisions. For more information visit https://go.cloudgenera.com/.

Proven Optics is helping you move from simplifying and centralizing your IT financials to supercharging your IT financial decision-making and execution.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240812664766/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye